Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone011-353-1772-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.21 billion
Profitability
Miscellaneous
Employees1,000
Next Earnings Date11/6/2019 (Confirmed)
OptionableOptionable
Horizon Therapeutics (NASDAQ:HZNP) Frequently Asked Questions
What is Horizon Therapeutics' stock symbol?
Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HZNP."
How were Horizon Therapeutics' earnings last quarter?
Horizon Therapeutics PLC (NASDAQ:HZNP) posted its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping the Zacks' consensus estimate of $0.38 by $0.14. The biopharmaceutical company had revenue of $320.60 million for the quarter, compared to the consensus estimate of $296.27 million. Horizon Therapeutics had a return on equity of 30.33% and a net margin of 5.90%. The company's quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.48 EPS. View Horizon Therapeutics' Earnings History.
When is Horizon Therapeutics' next earnings date?
How can I listen to Horizon Therapeutics' earnings call?
Horizon Therapeutics will be holding an earnings conference call on Wednesday, November 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Horizon Therapeutics issued on next quarter's earnings?
Horizon Therapeutics updated its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.28-1.3 billion, compared to the consensus revenue estimate of $1.26 billion.
What price target have analysts set for HZNP?
12 equities research analysts have issued 12-month target prices for Horizon Therapeutics' shares. Their forecasts range from $27.00 to $38.00. On average, they expect Horizon Therapeutics' share price to reach $33.67 in the next twelve months. This suggests a possible upside of 19.4% from the stock's current price. View Analyst Price Targets for Horizon Therapeutics.
What is the consensus analysts' recommendation for Horizon Therapeutics?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Horizon Therapeutics.
What are Wall Street analysts saying about Horizon Therapeutics stock?
Here are some recent quotes from research analysts about Horizon Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, ". We have updated our financial model to include: 1) HZNP’s recent equity offering, and 2) sales for teprotumumab starting in 2020, given the positive Phase 3 results earlier this year. Both the equity raise and positive Phase 3 data support our OW rating on HZNP shares. Therefore, we are raising our PT to $32 from $26. The increase in our PT is driven by upward earnings revisions for 2020+ given we now include risk adjusted sales for teprotumumab in our financial model." (4/2/2019)
- 2. According to Zacks Investment Research, "Horizon faces intense competition from pharmaceutical and biotechnology companies, and universities and other research institutions.Horizon is working on label expansion of drug like Ravicti. Failing to gain regulatory approval for label expansions would hamper drugs’ commercial potential. The company is exploring a broader clinical profile of Krystexxa including adapting its MIRROR immunomodulation study based on promising recent data to support the potential for registration.The company’s clinical programs continue to advance, with the recent presentation of new teprotumumab phase II data that underscore the durable efficacy observed in thyroid eye disease. Shares of the company have outperformed the industry in the past year. Estimates have remained stable ahead of the Q4 results. The company has positive earnings surprise in the last few quarters." (2/8/2019)
- 3. Mizuho analysts commented, "We believe the event could have +10% upside/-30% downside to the stock (and is risky), because expectations for a positive read-out are already quite high. HZNP already advanced +17% YTD into the event. The company has discussed with us the opportunity as capturing 50% share in the 15,000-20,000 moderate/ severe active TED patients, with a $100K net price for treatment to achieve its estimates of >$750M. In contrast, we currently assume a ~15% share, and net price of $210K/treatment in 2020, with net price increases of 5% thereafter (based on prior mgmt. commentary on Orphan pricing). We will update our estimates after the data, which we believe will determine the commercial attractiveness of this compound. We reiterate our Neutral rating, and continue to view 2019 consensus earnings estimates as too high." (2/7/2019)
Has Horizon Therapeutics been receiving favorable news coverage?
News stories about HZNP stock have been trending very negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Horizon Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Horizon Therapeutics.
Are investors shorting Horizon Therapeutics?
Horizon Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 6,990,000 shares, an increase of 8.4% from the August 30th total of 6,450,000 shares. Based on an average trading volume of 1,360,000 shares, the days-to-cover ratio is currently 5.1 days. Currently, 3.8% of the shares of the company are sold short. View Horizon Therapeutics' Current Options Chain.
Who are some of Horizon Therapeutics' key competitors?
Some companies that are related to Horizon Therapeutics include Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Ionis Pharmaceuticals (IONS), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC) and Perrigo (PRGO).
What other stocks do shareholders of Horizon Therapeutics own?
Who are Horizon Therapeutics' key executives?
Horizon Therapeutics' management team includes the folowing people:
- Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)
- Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)
- Dr. Shao-Lee Lin M.D., Ph.D., Exec. VP, Head of R&D and Chief Scientific Officer (Age 52)
- Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)
- Mr. Robert F. Carey, Exec. VP & Chief Bus. Officer (Age 60)
Who are Horizon Therapeutics' major shareholders?
Horizon Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Polianta Ltd (0.03%), First Hawaiian Bank (0.01%) and Juncture Wealth Strategies LLC (0.01%). Company insiders that own Horizon Therapeutics stock include Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani. View Institutional Ownership Trends for Horizon Therapeutics.
Which major investors are buying Horizon Therapeutics stock?
How do I buy shares of Horizon Therapeutics?
Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Horizon Therapeutics' stock price today?
One share of HZNP stock can currently be purchased for approximately $28.20.
How big of a company is Horizon Therapeutics?
Horizon Therapeutics has a market capitalization of $5.26 billion and generates $1.21 billion in revenue each year. The biopharmaceutical company earns $-74,190,000.00 in net income (profit) each year or $1.83 on an earnings per share basis. Horizon Therapeutics employs 1,000 workers across the globe.View Additional Information About Horizon Therapeutics.
What is Horizon Therapeutics' official website?
How can I contact Horizon Therapeutics?
Horizon Therapeutics' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]
MarketBeat Community Rating for Horizon Therapeutics (NASDAQ HZNP)
MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
